NCT03601260

Brief Summary

The aim of the study is to determine the percentage of cases of acute treatment with Allopurinol in gout patients who have been previously treated.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
700

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Aug 2018

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 18, 2018

Completed
8 days until next milestone

First Posted

Study publicly available on registry

July 26, 2018

Completed
6 days until next milestone

Study Start

First participant enrolled

August 1, 2018

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2018

Completed
Last Updated

July 26, 2018

Status Verified

July 1, 2018

Enrollment Period

4 months

First QC Date

July 18, 2018

Last Update Submit

July 18, 2018

Conditions

Gout

Outcome Measures

Primary Outcomes (1)

  • Gout patients treated with Allopurinol

    Retrospective identification through medical records of percentage of gout patients treated with Allopurinol

    Six months

Secondary Outcomes (1)

  • Patients with contraindication to Allopurinol

    Six months

Study Arms (1)

Gout Patients

OTHER

Allopurinol 100 mg-300mg/day as secondary treatment in gout patients

Drug: Allopurinol

Interventions

AllopurinolDRUG

Treatment of gout patients by oral dosage of 100 mg-300mg/ day of Allopurinol

Gout Patients

Eligibility Criteria

Age25 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Gout patients

You may not qualify if:

  • Pregnant women
  • Chronic renal failure
  • Patients with Allopurinal hypersensitivity

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hillel Yaffe Medical Center

Hadera, 38100, Israel

Location

MeSH Terms

Conditions

Gout

Interventions

Allopurinol

Condition Hierarchy (Ancestors)

ArthritisJoint DiseasesMusculoskeletal DiseasesCrystal ArthropathiesRheumatic DiseasesPurine-Pyrimidine Metabolism, Inborn ErrorsMetabolism, Inborn ErrorsGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesMetabolic DiseasesNutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

PurinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds

Central Study Contacts

Fadi Khalaila, MD

CONTACT

972-52-3326629khalailaf@yahoo.com

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 18, 2018

First Posted

July 26, 2018

Study Start

August 1, 2018

Primary Completion

December 1, 2018

Study Completion

December 1, 2018

Last Updated

July 26, 2018

Record last verified: 2018-07

Data Sharing

IPD Sharing
Will not share

Locations

IL(1)